Dexcom (DXCM) Q4 2020 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2020 earnings summary
4 Nov, 2026Executive summary
FY20 revenue rose 31% to $1.927B; gross margin reached 66%, operating income was $299.5M, and net income was $493.6M, including a material deferred-tax valuation allowance release.
Global CGM users exceeded 900,000 by year-end, with record annual new-customer additions; manufacturing capacity doubled in H1 despite pandemic challenges.
Financial highlights
Revenue increased $450.7M YoY to $1,926.7M, led by higher disposable sensor volume; pricing pressure from channel strategy and product mix partly offset growth.
Gross profit rose 37% to $1,280.1M; gross margin improved to 66% from 63%, driven by revenue growth, product-design improvements and manufacturing efficiencies.
Operating income increased to $299.5M from $142.3M; R&D rose 32% to $359.9M and SG&A rose 20% to $620.7M.
Net income was $493.6M vs. $101.1M; diluted EPS was $5.06 vs. $1.10, with results boosted by the deferred-tax valuation allowance release.
Cash, cash equivalents and short-term marketable securities totaled $2.71B at year-end, up $1.18B YoY.
Outlook and guidance
Management expects cash, marketable securities, operating cash flows and available credit to cover anticipated operating and capital needs for at least the next 12 months.
2021 priorities include extending global CGM access and advancing G7; G7 is a one-piece disposable wearable with a 60% size reduction vs. G6.
Continued R&D investment is planned to develop next-generation products and services; pivotal G7 clinical work was completed, while COVID-related delays and supply disruption remain uncertainties.
Latest events from Dexcom
- Revenue growth and margin gains were offset by lower earnings and a major Verily charge.DXCM
Q4 2021 - Revenue grew 19% as G7 clearance and expanded CGM access strengthened growth prospects.DXCM
Q4 2022 - Revenue climbed 43% as profitability arrived and G6 capacity doubled.DXCM
Q4 2019 - G6-led revenue topped $1B as launch investment and the Verily charge widened losses.DXCM
Q4 2018 - Q3 revenue and margins grew, lifting FY2026 guidance and supporting a new $1B buyback.DXCM
Q3 2026 - Q4 revenue grew 26% organically as FDA submissions and G7 integrations advanced.DXCM
Q4 2023 - CONNECT data, expanded coverage, and product innovation set stage for accelerated growth.DXCM
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue rose 13%, net income 39%, margins and guidance up, $600M shares repurchased.DXCM
Q2 2026 - Q3 2024 saw 2–3% revenue growth, strong international gains, and a $750M share repurchase.DXCM
Q3 2024